| Literature DB >> 25837469 |
Marketa Kominkova1,2, Petr Michalek3,4, Kristyna Cihalova5,6, Roman Guran7,8, Natalia Cernei9,10, Lukas Nejdl11,12, Kristyna Smerkova13,14, Simona Dostalova15,16, Dagmar Chudobova17,18, Zbynek Heger19,20, Radek Vesely21, Jaromir Gumulec22,23, Jindrich Kynicky24, Kledi Xhaxhiu25, Ondrej Zitka26,27, Vojtech Adam28,29, Rene Kizek30,31.
Abstract
In this work, we focused on the differences between bacterial cultures of E. coli obtained from swabs of infectious wounds of patients compared to laboratory E. coli. In addition, blocking of the protein responsible for the synthesis of glutathione (γ-glutamylcysteine synthase-GCL) using 10 mM buthionine sulfoximine was investigated. Each E. coli showed significant differences in resistance to antibiotics. According to the determined resistance, E. coli were divided into experimental groups based on a statistical evaluation of their properties as more resistant and more sensitive. These groups were also used for finding the differences in a dependence of the glutathione pathway on resistance to antibiotics. More sensitive E. coli showed the same kinetics of glutathione synthesis while blocking GCL (Km 0.1 µM), as compared to non-blocking. In addition, the most frequent mutations in genes of glutathione synthetase, glutathione peroxidase and glutathione reductase were observed in this group compared to laboratory E.coli. The group of "more resistant" E. coli exhibited differences in Km between 0.3 and 0.8 µM. The number of mutations compared to the laboratory E. coli was substantially lower compared to the other group.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25837469 PMCID: PMC4425013 DOI: 10.3390/ijms16047210
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1A general procedure for the synthesis and metabolism of glutathione. γ-glutamylcysteine (γ-Glu-Cys) arises due to the γ-glutamylcysteine synthase (GCL) from glutamic acid (Glu) and cysteine (Cys). The reduced form of glutathion (GSH) is synthesized from GCL and glycine (Gly) due to the glutathione synthase (GSS). As an antioxidant, GSH is oxidized to form oxidized glutathione (GSSG) with the participation of the glutathione peroxidase (GPx). Thanks to the action of glutathione reductase (GR) glutathione occurs primarily in the form of GSH. γ-glutamyl transpeptidase (GGT) causes the glutathione degradation in the cells to glutamic acid (Glu) and dipeptide cysteinylglycine (Cys-Gly).
IC50 of buthionine sulfoximine (BSO) determined for E. coli. IC50 was determined from 24-h growth curves of E. coli with the applied BSO.
| Sample No. | 24IC50 (mM) |
|---|---|
| 1 | 25 |
| 2794 | 21 |
| 2252 | 16 |
| 2873 | 21 |
| 2642 | 25 |
| 2552 | 15 |
| 2250 | 17 |
| 2654 | 15 |
| 2869 | 24 |
Figure 2Comparison of MS profiles in pseudo-gel view of control E. coli (green dot) and of E. coli with blocked synthesis of GSH (red cross). The peak intensity is expressed in a gray scale—darker color of peak indicates higher peak intensity. The utilized mass range was 1–20 kDa.
Figure 3Effect of individual antibiotics on the size of inhibition zones. (A) Effect of BSO addition; and (B) combined effect of antibiotics and BSO. Results of ANOVA. Displayed as least squares weighted means and standard errors.
Figure 4The results of the hierarchical cluster analysis based on the E. coli resistance to the antibiotics. Distribution of patients according to the relation to antibiotics. Colors are indicated in patients who had greater resistance (R, yellow) or sensitivity (S, blue) to antibiotics.
Figure 5Presence of GSH in individual E. coli bacterial strains. Identification of E. coli is shown in the upper part of each image. Control variant is always highlighted in green and the variant with the blocked enzyme in red. (A) Determination of the concentration of GSH before and after the addition of amino acid precursors. Km are inscribed in graphs where the green dot indicates the control E. coli a red cross variant of E. coli with blocked synthesis of GSH; (B) Confirmation of the presence of GSH using MALDI-TOF MS—green curve indicates the control variant and red the blocked one.
Figure 6Level of gene expression of GSS, GPx and GR in E. coli obtained from the wounds of patients. Comparison of gene expression for the control E. coli (green), and E. coli with BSO, which blocks the synthesis of GSH on the level of GCL gene (red). The overlap of one or the other color over 50% indicates an increased expression compared with the other variant.
Mutations in GSS sequences. Position specified in the top line is highlighted bold in the table. Red letters represent the base, which compared with the control E. coli possesses a mutation at a given position. The sum of these mutations is given in the last column of the table.
| Sample | Position of Mutation | Number of Mutations | |||||
|---|---|---|---|---|---|---|---|
| 720 | 753 | 762 | 768 | 780 | 853 | ||
| 1 | …CG-G-
| …-
| …
| …
| …
| …
| - |
| 2794 | …CG- | …- | … | … | … | … | 7 |
| …CG-G-
| …-
| …
| …
| …
| …
| 0 | |
| 2873 | …CG-G | …- | …
| … | … | … | 6 |
| 2642 | …CG-G | …- | … | … | … | … | 6 |
| …CG-G | …-
| …
| …
| …
| …
| 1 | |
| …CG | …-
| …
| …
| …
| …
| 2 | |
| … | … | …
| … | … | … | 8 | |
| 2869 | …CG-G | …- | … | … | … | …
| 6 |
Mutations in GR sequences. Position specified in the top line is in the table highlighted bold. Red letters stand for the base, which compared with the control E. coli possesses a mutation at a given position. The sum of these mutations is given in the last column of the table.
| Sample | Position of Mutation | Number of Mutations | |||||
|---|---|---|---|---|---|---|---|
| 678 | 697 | 702 | 712 | 717 | 720 | ||
| 1 | …
| …
| …-T
| …
| …
| …
| - |
| 2794 | …
| …
| …-T
| …
| …
| …
| 6 |
|
| …
| …
| …- | …
| …
| …
| 3 |
| 2873 | …
| …
| …-T
| …
| …
| …
| 8 |
| 2642 | …
| …
| …- | …
| …
| …
| 4 |
| …
| …
| … | …
| …
| …
| 6 | |
| …
| …
| …- | …
| …
| …
| 4 | |
| …
| …
| …- | …
| …
| …
| 9 | |
| 2869 | …
| …
| …--
| …
| … | … | 8 |
Mutations in GPx sequences. Position specified in the top line is in the table highlighted bold. Red letters stand for the base, which compared with the control E. coli possesses a mutation at a given position. The sum of these mutations is given in the last column of the table.
| Sample | Position of Mutation | Number of Mutations | |
|---|---|---|---|
| 428 | 485 | ||
| 1 | …
| …
| - |
| 2794 | …
| …
| 3 |
| …
| …
| 1 | |
| 2873 | …
| …
| 3 |
| 2642 | …
| …
| 1 |
| …
| …
| 2 | |
| …
| …
| 2 | |
| …
| …
| 3 | |
| 2869 | …
| …
| 3 |
Figure 7Correlation between oxidative stress-related parameters and biochemical parameters of E. coli (A) size of inhibition zones for individual antibiotics (B). The effect of GSH on biochemical parameters is divided as follows: first, effect on the wavelength maximum of individual parameter and second, the effect on absorbance of individual biochemical parameter. The set of inhibition zones is tested natively and with the addition of BSO.
Characterization of wounds of patients from whom the swabs were obtained and E. coli subsequently cultured.
| Sample No. | Origin of Smear of Bacterial Infection | Lesion | DM | Sex | Age | Related Diseases | Duration of Treatment | Antibiotic Therapy |
|---|---|---|---|---|---|---|---|---|
| 1 | laboratory
| standard | NO | - | - | - | - | - |
| 2794 | relapse of perianal fistula | fistula | NO | W | 35 | severe obesity, * GERD, Dalacine intolerance | 28 days | Biseptol |
| 2252 | periproctal abscess, ** DM | abscess | YES | M | 85 | hypertension, ischemic heart disease, myocardial infarction, obesity | 4 days | without |
| 2873 | decubitus of left heel, insulin therapy in DM | decubitus | YES | M | 78 | hypertension, prostatic hyperplasia, osteosynthesis | 39 days | Augmentin, Amikin, Dalacin |
| 2642 | decubitus of sacrum | decubitus | NO | M | 83 | hyperplasia, incontinence, deep vein thrombosis, immobility | 47 days | Biseptol, Ciphin |
| 2552 | perianal abscess | abscess | YES | W | 43 | depression, uro-oncology findings, polyvalent drug allergy | 19 days | Augmentin, Ciphin, Metronidazol |
| 2250 | periproctal abscess, | abscess | YES | W | 43 | depression, uro-oncology findings, polyvalent drug allergy | 19 days | Augmentin, Ciphin, Metronidazol |
| 2654 | varicose ulcer of the right leg | ulcus | NO | W | 82 | myeloproliferative syndrome, immunosuppression—corticosteroids | 1 month | Augmentin |
| 2869 | decubitus of left heel, insulin therapy in DM | decubitus | YES | M | 78 | hypertension, prostatic hyperplasia, osteosynthesis | 39 days | Augmentin, Amikin, Dalacin |
* GERD—gastroesophageal reflux disease, ** DM—diabetes mellitus.